Trial Profile
A Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1654 in Pre-Term and Full-Term Infants
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 30 Nov 2023
Price :
$35
*
At a glance
- Drugs Clesrovimab (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- Acronyms MK-1654-002
- Sponsors Merck Sharp & Dohme Corp.
- 25 Sep 2022 Status changed from active, no longer recruiting to completed.
- 18 Oct 2021 Planned End Date changed from 22 Sep 2022 to 13 Sep 2022.
- 18 Oct 2021 Planned primary completion date changed from 22 Sep 2022 to 13 Sep 2022.